Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

Rhea-AI Summary

Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and report financial results for Q2 2023 on August 3, 2023. The conference call hosted by the senior management team will begin at 4:30 p.m. ET. Investors can access the webcast and submit written questions in advance. A replay of the webcast will be available on the company's website.

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click here
Date: Thursday, August 3, 2023 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13739413

Investors may submit written questions in advance of the conference call to ir@vaxart.com.

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

When will Vaxart provide a business update and report financial results for Q2 2023?

Vaxart will provide a business update and report financial results for Q2 2023 on August 3, 2023.

What time will the conference call begin?

The conference call will begin at 4:30 p.m. ET.

How can investors access the webcast?

Investors can access the webcast by visiting the company's website.

Can investors submit written questions in advance?

Yes, investors can submit written questions in advance of the conference call to ir@vaxart.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the company's website.